Literature DB >> 11505441

Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C.

F Puig-Basagoiti1, J C Sáiz, X Forns, S Ampurdanès, M Giménez-Barcons, S Franco, A Sánchez-Fueyo, J Costa, J M Sánchez-Tapias, J Rodés.   

Abstract

Two genomic regions of hepatitis C virus (HCV), the interferon sensitivity-determining region (ISDR) of the non-structural 5A gene (NS5A) and the protein kinase-RNA activated (PKR)-eukariotic transcription factor (eIF2-alpha) phosphorylation homology domain (PePHD) of the structural E2 gene, interact in vitro with the interferon-inducible cellular PKR protein kinase. Mutations within these regions might, therefore, influence the response to interferon therapy. Viral load at baseline and sequence heterogeneity of HCV in NS5A and E2 regions was studied in 74 HCV-1b and in 12 HCV-3a infected patients with chronic hepatitis C who were treated with interferon. As previously reported by us, in a smaller series of patients in which the ISDR region was analyzed [Saiz et al. (1998) Journal Infectious Diseases 177:839-847], in the present study a low viral load and a high number of amino acid mutations within the ISDR, but not within the PePHD region, were significantly associated with long-term response to interferon among HCV-1b infected patients. No relationship between these viral features and response to therapy was disclosed in patients infected with HCV-3a. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505441

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

Review 1.  The quasispecies nature and biological implications of the hepatitis C virus.

Authors:  Sarah L Fishman; Andrea D Branch
Journal:  Infect Genet Evol       Date:  2009-08-08       Impact factor: 3.342

2.  Mutations within the hepatitis C virus genotype 1b E2-PePHD domain do not correlate with treatment outcome.

Authors:  Catherine Gaudy; Marie Lambelé; Alain Moreau; Pascal Veillon; Francoise Lunel; Alain Goudeau
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

3.  The Relationship Between HCV-NS5A Gene Mutations and Resistance to Combination Therapy in Patients with HCV- Genotype 1-B.

Authors:  Hamed Esmaeil Lashgarian; Ali Valibeik; Abdolrazagh Marzban; Maryam Karkhane; Kiana Shahzamani
Journal:  Rep Biochem Mol Biol       Date:  2021-07

Review 4.  The hepatitis C virus persistence: how to evade the immune system?

Authors:  Nicole Pavio; Michael M C Lai
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

5.  Predictive factors for interferon and ribavirin combination therapy in patients with chronic hepatitis C.

Authors:  Joonho Yoon; Jong In Lee; Soon Koo Baik; Kwang Ho Lee; Joon Hyung Sohn; Hyean Woo Lee; Jun Namkung; Sei Jin Chang; Jong Whan Choi; Hyun Won Kim; Byung-Il Yeh
Journal:  World J Gastroenterol       Date:  2007-12-14       Impact factor: 5.742

6.  Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences.

Authors:  M Pascu; P Martus; M Höhne; B Wiedenmann; U Hopf; E Schreier; T Berg
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

7.  Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype.

Authors:  Celia Perales; Nathan M Beach; Isabel Gallego; Maria Eugenia Soria; Josep Quer; Juan Ignacio Esteban; Charles Rice; Esteban Domingo; Julie Sheldon
Journal:  J Virol       Date:  2013-05-01       Impact factor: 5.103

8.  The hepatitis C virus NS5A protein and response to interferon alpha: mutational analyses in patients with chronic HCV genotype 3a infection from India.

Authors:  Ankur Goyal; Wolf P Hofmann; Eva Hermann; Stella Traver; Syed S Hissar; Naveen Arora; Hubert E Blum; Stefan Zeuzem; Christoph Sarrazin; Shiv K Sarin
Journal:  Med Microbiol Immunol       Date:  2006-09-06       Impact factor: 3.402

9.  Amino Acid Polymorphisms Within the Entire HCV NS5A Region in Estonian Chronic HCV 1b Patients With Different Treatment Response.

Authors:  Tatiana Kuznetsova; Tatjana Tallo; Vadim Brjalin; Irina Reshetnjak; Riina Salupere; Ljudmilla Priimagi; Olga Katargina; Maria Smirnova; Juris Jansons; Valentina Tefanova
Journal:  Hepat Mon       Date:  2013-12-14       Impact factor: 0.660

10.  Hepatitis C virus diversity and evolution in the full open-reading frame during antiviral therapy.

Authors:  Nathan A Cannon; Maureen J Donlin; Xiaofeng Fan; Rajeev Aurora; John E Tavis
Journal:  PLoS One       Date:  2008-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.